Safety and Efficacy Study of Daclizumab High Yield Process to Treat Relapsing-Remitting Multiple Sclerosis (SELECT)

This study has been completed.
Information provided by (Responsible Party):
Biogen Idec Identifier:
First received: October 17, 2006
Last updated: September 12, 2013
Last verified: May 2013

The purpose of this study is to determine the effect of 2 different doses of daclizumab on reducing relapses in subjects with relapsing-remitting MS.

Primary Objective:

The primary objective of this study is to determine whether Daclizumab High Yield Process, when compared to placebo, is effective in reducing the rate of relapses between baseline and Week 52.

Secondary Objectives:

The secondary objectives are to determine whether Daclizumab High Yield Process is effective in:

  • reducing the number of new Gd-enhancing lesions over 5 brain MRI scans at Weeks 8, 12, 16, 20, and 24 (calculated as the sum of these 5 MRIs) in a subset of subjects.
  • reducing the number of new or newly-enlarging T2 hyperintense lesions at Week 52,
  • reducing the proportion of relapsing subjects between baseline and Week 52,
  • improving quality of life as measured by the Multiple Sclerosis Impact Scale (MSIS)-29 physical score at Week 52 compared to baseline.

Condition Intervention Phase
Multiple Sclerosis, Relapsing-remitting
Biological: Daclizumab High Yield Process
Other: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis

Resource links provided by NLM:

Further study details as provided by Biogen Idec:

Primary Outcome Measures:
  • Annualized Relapse Rate [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Brain MRI measures (number of gd-enhancing lesions) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Proportion of relapsing subjects [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Improving quality of life as measured by Multiple Sclerosis Impact Scale (MSIS)-29 physical score [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Brain MRI measures (number of new or newly-enlarging T2 hyperintense lesions) [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment: 621
Study Start Date: February 2008
Study Completion Date: August 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
subcutaneous (SC)
Other: placebo
Experimental: 2
Daclizumab High Yield Proces (Subcutaneous)
Biological: Daclizumab High Yield Process
150 mg (Subcutaneous) every 4 weeks for 48 weeks
Experimental: 3
Daclizumab High Yield Proces (Subcutaneous)
Biological: Daclizumab High Yield Process
300 mg (Subcutaneous) every 4 weeks for 48 weeks

Detailed Description:

Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects approximately 400,000 persons in North America and 365,000 persons in Europe. Daclizumab High Yield Process (DAC HYP) is being co-developed by Biogen Idec Inc. (Biogen Idec) and AbbVie for treatment of MS. Daclizumab (DAC) produced using the AbbVie high-yield process is being investigated as an alternative. This study will determine if DAC HYP is safe and efficacious in subjects with relapsing-remitting multiple sclerosis (MS). A dose exploration placebo controlled study will be performed. Proof of profile will be sought that targeting of the alpha chain of the interleukin-2 receptor (IL-2Ralpha) without concomitant interferon (IFN) is effective in subjects with relapsing-remitting MS.


Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • MS subjects who have a confirmed diagnosis of relapsing-remitting MS according to McDonald criteria #1-4 and a baseline EDSS (Expanded Disability Status Scale) between 0.0 and 5.0, inclusive, who meet either of the following 2 criteria

    • Have experienced at least 1 relapse within the 12 months prior to randomization, with a cranial MRI demonstrating lesion(s) consistent with MS , OR
    • Show evidence of gadolinium-enhancing lesions of the brain on an MRI performed within the 6 weeks prior to randomization.

Exclusion Criteria:

  • Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS
  • History of malignancy
  • History of severe allergic or anaphylactic reactions or known drug hypersensitivity
  • History of abnormal laboratory results
  • History of human immunodeficiency virus (HIV) or other immunodeficient conditions
  • History of drug or alcohol abuse ithin the 2 years prior to randomization
  • An MS relapse that has occurred within the 50 days prior to randomization AND/OR the subject has not stabilized from a previous relapse prior to randomization
  • Positive screening for active infection with Hepatitis B virus or Hepatitis C virus
  • Varicella or herpes zoster virus infection or any severe viral infection within 6 weeks before Screening
  • Exposure to varicella zoster virus within 21 days before Screening.
  • Abnormal blood tests at Screening; Hemoglobin ≤9.0 g/dL, Platelets ≤100 × 109/L, Lymphocytes ≤1.0 × 109/L, Neutrophils ≤1.5 × 109/L, alanine aminotransferase/serum glutamate pyruvate transaminase (ALT/SGPT), aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), or gamma-glutamyl-transferase >2 times the upper limit of normal (ULN) and serum creatinine >ULN.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00390221

  Hide Study Locations
Czech Republic
Research Site
Brno, Czech Republic, 65691
Research Site
Brno, Czech Republic, 62500
Research Site
Hradec Kralove, Czech Republic, 50005
Research Site
Olomouc, Czech Republic, 77520
Research Site
Plzen, Czech Republic, 30460
Research Site
Prague, Czech Republic, 10034
Research Site
Teplice, Czech Republic, 41529
Research Site
Bayreuth,, Germany, 95445
Research Site
Erlangen, Germany, 91054
Research Site
Marburg, Germany, 35033
Research Site
Osnabrueck, Germany, 49076
Research Site
Regensburg, Germany, 93053
Research Site
Rostock, Germany, 18147
Research Site
Budapest, Hungary, 1076
Research Site
Budapest, Hungary, 1083
Research Site
Budapest, Hungary, 1134
Research Site
Budapest, Hungary, 1115
Research Site
Budapest, Hungary, 1125
Research Site
Debrecen, Hungary, 4043
Research Site
Debrecen, Hungary, 4012
Research Site
Esztergom, Hungary, 2500
Research Site
Gyor, Hungary, 9024
Research Site
Kecskemet, Hungary, 6000
Research Site
Miskolc, Hungary, 3529
Research Site
Miskolc, Hungary, 3526
Research Site
Nyiregyhaza, Hungary, 4400
Research Site
Siofok, Hungary, 8600
Research Site
Zalaegerszeg, Hungary, 8900
Research Site
Andra-Pradeash, India, 500082
Research Site
Bangalore, India, 560034
Research Site
Kolkata, India, 700068
Research Site
Mumbai, India, 400012
Research Site
Rajastan, India, 302017
Research Site
Vishakhapatnam, India, 530002
Research Site
Bialystok, Poland, 15276
Research Site
Bialystok, Poland, 15420
Research Site
Gdansk, Poland, 80803
Research Site
Katowice, Poland, 93121
Research Site
Katowice, Poland, 40753
Research Site
Krakow, Poland, 31530
Coordinating Research Site
Lodz, Poland, 90153
Research Site
Lodz, Poland, 93121
Research Site
Lublin, Poland, 20954
Research Site
Warsaw, Poland, 2957
Research Site
Warszawa, Poland, 2097
Russian Federation
Research Site
Kazan, Russian Federation, 420021
Research Site
Krasnoyarsk, Russian Federation, 660022
Research Site
Moscow, Russian Federation, 107150
Research Site
Moscow, Russian Federation, 115682
Research Site
Moscow, Russian Federation, 12708
Research Site
Nizhniy Novgorod, Russian Federation, 603076
Research Site
Novosibirsk, Russian Federation, 630007
Research Site
Omsk, Russian Federation, 644099
Research Site
Samara, Russian Federation, 443099
Research Site
Smolensk, Russian Federation, 214019
Research Site
St Petersburg, Russian Federation, 194291
Research Site
St Petersburg, Russian Federation, 194044
Research Site
Ufa, Russian Federation, 450000
Research Site
Yaroskavi, Russian Federation, 150030
Research Site
Chernivtsy, Ukraine, 58018
Research Site
Dnipropetrovsk, Ukraine, 49027
Research Site
Donetsk, Ukraine, 83003
Research Site
Kharkiv, Ukraine, 61068
Research Site
Kharkiv, Ukraine
Research Site
Kiev, Ukraine, 2125
Research Site
Kiev, Ukraine, 3110
Research Site
Kyiv, Ukraine, 3110
Research Site
Lviv, Ukraine, 79010
Research Site
Poltava, Ukraine, 360011
Research Site
Zaporozhye, Ukraine, 69600
Research Site
Zaporozhye, Ukraine, 69035
United Kingdom
Research Site
London, United Kingdom, SE59RF
Research Site
Nottingham, United Kingdom, NG72UH
Research Site
Plymouth, United Kingdom, PL68DH
Research Site
Sheffield, United Kingdom, S102JF
Research Site
Stoke-on-Trent, United Kingdom, ST47LN
Sponsors and Collaborators
Biogen Idec
  More Information

Additional Information:
No publications provided by Biogen Idec

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Biogen Idec Identifier: NCT00390221     History of Changes
Other Study ID Numbers: 205-MS-201
Study First Received: October 17, 2006
Last Updated: September 12, 2013
Health Authority: Ukraine: State Pharmacological Center - Ministry of Health
Czech Republic: State Institute for Drug Control
Hungary: National Institute of Pharmacy
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
India: Drugs Controller General of India
Turkey: Ministry of Health
Germany: Paul-Ehrlich-Institut
Russia: Ministry of Health of the Russian Federation

Keywords provided by Biogen Idec:
multiple sclerosis

Additional relevant MeSH terms:
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes
Immunoglobulin G
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions processed this record on September 22, 2014